Market Overview

Biotech Stocks Soar Amid Positive News

Share:

A number of biotech stocks were soaring in Friday's premarket following positive news.

Biogen Idec Inc (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037) which showed statistical significance with 3mg, 10mg doses for Alzheimer's treatment.

Biogen Idec traded at $464.71 in the premarket, up 7.16 percent

Gilead Sciences, Inc. (NASDAQ: GILD) moved higher following positive comments from Argus, which expected continued strength for its antiviral and oncology drugs.

Gilead Sciences traded at $102.40, up 0.95 percent.

Prothena Corporation PLC (NASDAQ: PRTA) reported that its PRX002 protein Immunotherapy for Parkinson's Disease met primary objective of Phase 1 study, found to be safe, well tolerated.

Prothena soared to $41.87 in the premarket, up 43.24 percent.

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported that data showed OCA-treated patients with nonalcoholic steatohepatitis (NASH) saw improvements in its Phase 2b FLINT trial.

Intercept Pharmaceuticals surged 8 percent to $311.71.

Posted-In: Biotech News Movers General

 

Related Articles (BIIB + GILD)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

KB Home Tops Q1 Estimates. Shares Surge

Credit Suisse Raises Estimates On 1Q Beat For Lennar